申请人:Grelan Pharmaceutical Co., Ltd.
公开号:US06642250B2
公开(公告)日:2003-11-04
The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1):
wherein:
A is an unsubstituted or optionally substituted 5 or 6 membered heteroaryl group or a fused benzene ring in which any of the above-defined heteroaryl groups is fused to a benzene ring,
B is carbon or nitrogen,
R1 is hydrogen, lower alkyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group,
R2 is hydrogen, halogen, cyano, nitro, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, and
m is an integer of from 1 to 8, both inclusive;
or a pharmaceutically acceptable salt thereof possesses selective PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.
本文的目的是提供具有强效抗哮喘特性和优异安全性的选择性PDE IV抑制剂。化合物的公式(1)如下:其中:A是未取代或可选择取代的5或6元杂环基或融合苯环,其中上述任何杂环基都与苯环融合;B是碳或氮;R1是氢、低碳基、三氟甲基、羟基、低烷氧基、来自羧酸或其衍生物的残基、氨基或含氨基氮的基团;R2是氢、卤素、氰基、硝基、低烷基硫基、低烷基亚砜基、低烷基磺酰基、三氟甲基、羟基、低烷氧基、来自羧酸或其衍生物的残基、氨基或含氨基氮的基团;m是1至8的整数,包括1和8;或其药学上可接受的盐具有选择性的PDE IV抑制作用,并且可用作药物,优选用作抗哮喘药物等。